Dr. Versha Banerji
Claim this profileCancer Care Manitoba
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
4 reported clinical trials
8 drugs studied
Area of expertise
1Lymphoma
13q positive
13q negative
12 positive
2Chronic Lymphocytic Leukemia
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Versha Banerji is currently running
Pirtobrutinib vs Ibrutinib
for Chronic Lymphocytic Leukemia
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Recruiting2 awards Phase 3
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Versha Banerji
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Versha Banerji has experience with
- Rituximab
- Venetoclax
- Pirtobrutinib
- Bendamustine
- Idelalisib
- LOXO-305
Breakdown of trials Versha Banerji has run
Lymphoma
Chronic Lymphocytic Leukemia
Childhood Blood Disease
Mediastinal Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Versha Banerji specialize in?
Versha Banerji focuses on Lymphoma and Chronic Lymphocytic Leukemia. In particular, much of their work with Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Versha Banerji currently recruiting for clinical trials?
Yes, Versha Banerji is currently recruiting for 2 clinical trials in Winnipeg Manitoba. If you're interested in participating, you should apply.
Are there any treatments that Versha Banerji has studied deeply?
Yes, Versha Banerji has studied treatments such as Rituximab, Venetoclax, Pirtobrutinib.
What is the best way to schedule an appointment with Versha Banerji?
Apply for one of the trials that Versha Banerji is conducting.
What is the office address of Versha Banerji?
The office of Versha Banerji is located at: Cancer Care Manitoba, Winnipeg, Manitoba R3E 0V9 Canada. This is the address for their practice at the Cancer Care Manitoba.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.